| Artificial intelligence in early drug discovery enabling precision medicine F Boniolo, E Dorigatti, AJ Ohnmacht, D Saur, B Schubert, MP Menden Expert Opinion on Drug Discovery 16 (9), 991-1007, 2021 | 107 | 2021 |
| The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer AJ Ohnmacht, A Stahler, S Stintzing, DP Modest, JW Holch, ... Nature communications 14 (1), 5391, 2023 | 9 | 2023 |
| Can artificial intelligence accelerate preclinical drug discovery and precision medicine? A Farnoud, AJ Ohnmacht, M Meinel, MP Menden Expert Opinion on Drug Discovery 17 (7), 661-665, 2022 | 6 | 2022 |
| The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity AJ Ohnmacht, A Rajamani, G Avar, G Kutkaite, E Gonçalves, D Saur, ... Communications Biology 6 (1), 825, 2023 | 5 | 2023 |
| Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial … JW Holch, AJ Ohnmacht, S Stintzing, K Heinrich, B Westphalen, L Weiss, ... Journal of Clinical Oncology 42 (3_suppl), 13-13, 2024 | 2 | 2024 |
| Inferred ancestral origin of cancer cell lines associates with differential drug response PBH Nguyen, AJ Ohnmacht, S Sharifli, MJ Garnett, MP Menden International Journal of Molecular Sciences 22 (18), 10135, 2021 | 2 | 2021 |
| The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines AJ Ohnmacht, G Avar, MK Schübel, TJ O’Neill, D Krappmann, ... bioRxiv, 2024.01. 16.575190, 2024 | 1 | 2024 |
| Enhancing Gene Expression Representation and Drug Response Prediction with Data Augmentation and Gene Emphasis D Lu, DPS Pamar, AJ Ohnmacht, G Kutkaite, MP Menden bioRxiv, 2024.05. 15.592959, 2024 | | 2024 |
| DNA methylation profiling refines the prognostic classification of acute myeloid leukemia patients treated with intensive chemotherapy S Vosberg, AJ Ohnmacht, C Moser, A Arneth, V Jurinovic, KH Metzeler, ... HemaSphere 6, 378-379, 2022 | | 2022 |
| FOLFIRI with Cetuximab or Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer: Refining First-Line Treatment Selection by Combining Clinical Parameters-A post hoc … JW Holch, AJ Ohnmacht, S Stintzing, K Heinrich, L Weiss, V Probst, ... | | |